ISSN: 2167-065X

Pharmacologie clinique et biopharmaceutique

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Effect of Evidence-Based Nursing Practise on Protocol Adherence inClinical Trials of Anticancer Drugs

Fengzhen Chen

This study aimed to construct evidence-based malignant neoplasm drug run nursing management norms to confirm the security and quality of run nursing. This before-after study was allotted to finish the proof implementation in an exceedingly cancer hospital in Shanghai, China. Seven review indicators were developed and reviewed in one {phase I run phase I clinical trial clinical test} clinical trial center and 2 medical specialty wards. The corresponding evidencebased intervention program was developed, and also the completion rate of excellent clinical observe certification, protocol coaching, delegation of duties, qualification rate of administration, sampling and document recording in malignant neoplasm drug clinical trials before and once implementation were compared. After implementation, the completion rate of protocol coaching, delegation of duties, and also the qualification rate of document recording were considerably more than those of the baseline review, whereas the completion rate of excellent clinical observe certification and also the qualification rate of sampling failed to considerably disagree from those discovered at the baseline review. There was no administration or infusion device-related protocol deviation throughout the baseline and post reviews.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.